Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan)

Bagsværd, Denmark, 26 May 2023 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use...

Related Keywords

Denmark ,Martin Holst Lange ,Growth Hormone Research Society ,European Commission ,Gh Research Society ,Development At Novo Nordisk ,European Medicines Agency ,Us Food Drug Administration ,Committee For Medicinal Products Human Use ,National Organization For Rare Disorders ,Novo Nordisk ,Medicinal Products ,Human Use ,Drug Administration ,Growth Hormone ,Best Pract Res Clin Endocrinol ,Treatment Burden ,Children Treated ,Well Tolerated ,Children With ,Randomized Phase ,Research Study ,Low Level ,Somapacitan Once ,Week Compared ,Opin Endocrinol Diabetes ,Childhood Published Online First ,Hormone Research ,Insulin Like Growth Factori Treatment ,Growth Hormone Deficiency ,Idiopathic Short Stature ,Primary Insulin Like Growth Factor I ,Horm Res ,Copenhagen Stock Exchange Novo B ,Novo Nordiska S ,